Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interferon · 1 trial · 1 indication
Progression-free Survival (PFS) was defined as the time from date of randomization to disease progression (radiological or clinical or death due to any cause, whichever occurs first). Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation
| Arm | Type | Description |
|---|---|---|
| First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg | EXPERIMENTAL | Subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (bid) (ie 12-hourly) orally until progression (= first intervention period, 5.7 months \[median\] ) and 3 tablets of Sorafenib twice daily (ie 12-hourly) orally until the following progression (= second intervention period, 3.6 months \[median\]) on a continuous basis. |
| First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg | ACTIVE_COMPARATOR | Interferon (IFN) α-2a was administered at a dose of 9 million international units(MIU) subcutaneously three times a week until progression (= first intervention period, 5.6 months \[median\]). Subjects initially started with a single dose of 3 MIU IFN and increased the dose as rapidly as possible to 9 MIU IFN three times a week within 1 or 2 weeks in first intervention period.After first progression, subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (BID) (ie 12-hourly) until the next progression (=second intervention period, 5.3 months \[median\]). |
| Name | Type | Description |
|---|---|---|
| Sorafenib (Nexavar, BAY43-9006) | DRUG | Multi kinase inhibitor |
| Interferon | DRUG | Interferon |
Inclusion Criteria: * Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice * Male or female patients \>= 18 years of age * Patients who have a life ...
Interferon is being studied for the treatment of unresectable and/or metastatic renal cell carcinoma, a type of kidney cancer. It is currently in Phase 2 clinical development as an investigational therapy for this condition.
Interferon is being developed by Bayer AG, a pharmaceutical company traded on the OTC market under the ticker symbol BAYRY. The company is conducting clinical research to evaluate the drug's safety and efficacy in renal cell carcinoma.
Interferon is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed to assess its use in patients with renal cell carcinoma.
Interferon has been studied in a completed Phase 2 clinical trial with the identifier NCT00117637. This trial enrolled 189 patients with unresectable and/or metastatic renal cell carcinoma and compared Interferon against an active control treatment.
No, Interferon is not the same as BAY43-9006 (Sorafenib). In the clinical trial NCT00117637, Interferon was compared against Sorafenib as an active control. Interferon is a separate investigational drug being evaluated for renal cell carcinoma.